said the positive opinion includes the tablet form of Sprycel and the powder for oral suspension formulation, which was first approved by the European Commission in July 2018, making Sprycel the only tyrosine kinase inhibitor with a formulation developed for administration in pediatric patients and patients who cannot swallow tablets.
said the transaction includes upfront and near-term milestone payments of up to USD 300m and potential additional consideration of up to USD 1.775bn upon the achievement of certain development, regulatory and sales milestones.
28 October 2013 -- Financial services firms Deutsche Bank Securities (NYSE: DB) JP Morgan Securities (NYSE: JPM) Barclays Capital Inc BNP Paribas Securities Credit Suisse Securities (NYSE: CS) and RBS Securities (NYSE: RBS) are acting as joint book-running managers of New York-based drugmaker Bristol-Myers Squibb Co's (NYSE: BMY
) public offering of notes.
This means that BMY
no longer has to use composites or maraging steel, and can reduce the number of bridge hydraulics units from 12 to eight, while staying within the Army's weight limit for the bridge.
Comment: To address concerns expressed by the FTC, BMY
is planning the divestiture of Otzela (apremilast).
According to BMY
, the FDA granted the application priority review and previously granted Opdivo orphan-drug designation for the treatment of HCC.
Publisher, Bloomsbury Publishing (FTSE: BMY
.L), has reported another strong growth in profits thanks to the continuing Harry Potter phenomenon.
William Blair analyst Matt Phipps said Bristol-Myers (BMY
) suffered a "double hit to sentiment" yesterday with the news of both the CheckMate-459 trial failure in first-line hepatocellular carcinoma and delay of the closing of its Celgene (CELG) deal due to the required Otezla divestiture.
US-based pharmaceutical company Bristol-Myers Squibb Company (NYSE: BMY
) has named the future leadership team of the combined company effective upon completion of the company's pending merger with Celgene Corp.
- The US Food and Drug Administration accepted a supplemental Biologics License Application that seeks to extend the use of US-based pharmaceutical company Bristol-Myers Squibb Co's (NYSE: BMY
) Opdivo (nivolumab) to patients with mismatch repair deficient or microsatellite instability high (MSI-H) metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, the company said.
Tenders are invited for TTR (FS+CS+CMSC)- 90 sets in BMY
Yard of Raipur Division
M2 EQUITYBITES-October 28, 2013-- Deutsche, JP Morgan, Barclays, BNP Paribas, Credit Suisse and RBS lead BMY
offering(C)2013 M2 COMMUNICATIONS http://www.m2.com